1. Scrip
  2. >>Business
  3. >>Earnings

Novartis Positive Post-Sandoz But Some Cancer Drugs Look Lackluster

 
• By Elizabeth Cairns

Sans Sandoz, Novartis posts a beat-and-raise but its oncology franchise remains undistinguished.  

Novartis

Pluvicto is forecast to be Novartis AG’s fourth biggest-selling drug in 2028, with worldwide sales of $3.4bn according to Evaluate Pharma consensus data, but this figure might have to be revised downwards after the Swiss group confirmed during its third quarter results that the radiopharmaceutical’s supplemental filings in prostate cancer would be delayed from this year to next.

Key Takeaways
  • Novartis’s Q3 results beat analysts’ expectations
  • But radiopharmaceutical Pluvicto’s prostate cancer label expansions will be delayed
  • Breast cancer drug Kisqali will overtake Pfizer’s Ibrance in 2025 but...

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is approved in Europe and the US for prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) patients who have been treated with androgen...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

More from Business

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.